Compare BVS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | ADCT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.1M | 484.4M |
| IPO Year | 2016 | 2019 |
| Metric | BVS | ADCT |
|---|---|---|
| Price | $10.53 | $4.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.00 | $7.75 |
| AVG Volume (30 Days) | 440.5K | ★ 741.8K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | 30.86 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | $81,357,000.00 |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $7.06 | $66.49 |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $5.81 | $1.20 |
| 52 Week High | $10.58 | $4.98 |
| Indicator | BVS | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 74.48 | 69.10 |
| Support Level | $8.43 | $3.28 |
| Resistance Level | N/A | $4.77 |
| Average True Range (ATR) | 0.36 | 0.27 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 94.99 | 85.29 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).